Skip to content
mapperlab
← Dashboard
Stock

CRBU

Caribou Biosciences, Inc.
Latest close $2.077 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
9
Current + past
New this quarter
0
Exited this quarter
0

Marquee-fund ownership over time

Nov 12, 2021Feb 14, 2023Feb 13, 2025Aug 14, 2025
Now
7

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Maverick Capital$22$2.07-90%
Renaissance Technologies re-entered$1.94$2.07+7%
Citadel Advisors re-entered$1.90$2.07+9%
Two Sigma Investments$1.90$2.07+9%
AQR Capital Management$1.90$2.07+9%
Millennium Management$1.90$2.07+9%
Point72 Asset Management$1.90$2.07+9%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Duquesne Family Office—+0%
Coatue Management→ $9.74-55%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Caribou Biosciences, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
14
Filings · last 90d
14
Total on file
102
Recent SEC buffer
Most recent
Feb 27, 2026

30d / 90d windows measured from Feb 27, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 102 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Caribou Biosciences, Inc.

Annual figures sourced directly from Caribou Biosciences, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$11.16M
FY2025+12% YoY
Net income
-$148.13M
FY2025+1% YoY
EPS (diluted)
$-1.59
FY2025+4% YoY
Free cash flow(?)
-$112.35M
FY2025+21% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Caribou Biosciences, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Citadel AdvisorsQ3 2025open$2.00$2.07+3%
Renaissance TechnologiesQ3 2025open$1.95$2.07+6%
Citadel AdvisorsQ3 2024Q1 2025$1.90$1.35-29%
Two Sigma InvestmentsQ3 2024open$1.90$2.07+9%
AQR Capital ManagementQ3 2024open$1.90$2.07+9%
Millennium ManagementQ3 2024open$1.90$2.07+9%
Point72 Asset ManagementQ3 2024open$1.90$2.07+9%
Renaissance TechnologiesQ3 2024Q1 2025$1.94$1.31-32%
Maverick CapitalQ4 2021open$22$2.33-89%
Duquesne Family OfficeQ4 2021Q1 2023$0.00—+0%
Coatue ManagementQ4 2021Q2 2022$22$9.74-55%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.